v3.26.1
OPERATING SEGMENTS
 9 Months Ended
Mar. 31, 2026
OPERATING SEGMENTS  
OPERATING SEGMENTS

4. OPERATING SEGMENTS

 

Operating segments are defined as components of an entity for which separate financial information is available that is regularly reviewed by the chief operating decision maker (“CODM”). The CODM is the Chief Executive Officer. The CODM uses segment net income from operations to assess the performance of, manage the operations of, and allocate capital and operational resources to the Company’s reportable operating segments. The Company does not allocate assets to the reporting segments as its assets are primarily managed on an entity-wide basis and therefore does not disclose the total assets of its reportable operating segments.

 

Prior to June 11, 2025, the Company operated as a single operating segment, focusing on distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management.

 

Starting June 11, 2025, the Company has two reportable segments, focusing on distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management and developing real estate opportunities, designed to attract healthcare providers and wellness clinic operators.

 

For the three and nine months ended March 31, 2026, there were no intersegment revenues or costs of revenues that needed to be eliminated in the Consolidated Statements of Operations.

 

The pharmaceutical products distribution company generates revenue through product sales, commissions, and online sales. Real estate development company generates revenue through rental income.

 

The following table illustrates segment revenue and segment net income from operations, including significant expense items reviewed by the CODM for the three months ended March 31, 2026.

 

 

 

Pharmaceutical Products Distribution

 

 

Real Estate Development

 

 

Total

 

Revenue

 

$596,176

 

 

$22,500

 

 

$618,676

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues - product sales

 

 

466,004

 

 

 

-

 

 

 

466,004

 

Cost of revenues - rent

 

 

-

 

 

 

7,500

 

 

 

7,500

 

General and administrative[1]

 

 

356,414

 

 

 

8,125

 

 

 

364,539

 

Depreciation and amortization

 

 

6,124

 

 

 

2,448

 

 

 

8,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment net income (loss) from operations

 

$(232,366 )

 

$4,427

 

 

$(227,939 )

[1]

General and administrative costs consist mainly of professional fees, salaries and wages, executive compensation, information technology and software, and other payment processing fees.

 

The following table illustrates the reconciliation of segment operating income to net income before taxes for the three months ended March 31, 2026.

 

 

 

March 31, 2026

 

Segment loss from operations

 

$(227,939 )

 

 

 

 

 

Reconciling items

 

 

 

 

Interest expense

 

 

(12,725 )

 

 

 

 

 

Net income (loss) from continued operations before income taxes

 

$(240,664 )

 

 

The following table illustrates segment revenue and segment net income from operations, including significant expense items reviewed by the CODM for the nine months ended March 31, 2026.

 

 

 

Pharmaceutical Products Distribution

 

 

Real Estate Development

 

 

Total

 

Revenue

 

$1,626,982

 

 

$67,500

 

 

$1,694,482

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues - product sales

 

 

1,256,774

 

 

 

-

 

 

 

1,256,774

 

Cost of revenues - rent

 

 

-

 

 

 

23,775

 

 

 

23,775

 

General and administrative[1]

 

 

1,192,069

 

 

 

24,375

 

 

 

1,216,444

 

Depreciation and amortization

 

 

18,373

 

 

 

7,077

 

 

 

25,450

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment net income (loss) from operations

 

$(840,234 )

 

$12,273

 

 

$(827,961 )

[1]

General and administrative costs consist mainly of professional fees, salaries and wages, executive compensation, information technology and software, and other payment processing fees.

 

The following table illustrates the reconciliation of segment operating income to net income before taxes for the three months ended March 31, 2026.

 

 

 

March 31, 2026

 

Segment loss from operations

 

$(827,961 )

 

 

 

 

 

Reconciling items

 

 

 

 

Interest Expense

 

 

(39,290 )

Loss on exchange of Series C & D preferred shares

 

 

(241,918 )

 

 

 

 

 

Net income (loss) from continued operations before income taxes

 

$(1,109,169 )